DrugBiological
Sugemalimab clinical trials
Also written CS1001.
- studies test it
- 16
- open now
- 5
- in phase 3
- 6
- first study started
- 2017
Keep track of what changes. Save the sugemalimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
15 studies that test it; most in 2018 (5); 1 more planned to start later
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 5 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 3 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 6
- Phase 3
- 6
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 4
CStone Pharmaceuticals (11) · Sichuan University (1) · Peking Union Medical College (1) · Sun Yat-sen University (1) · Hunan Cancer Hospital (1) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (1)
Often tested with
Tested in the same studies.
Fluorouracil (1) · Cisplatin (1) · Regorafenib (1) · Olaparib (1) · Donafenib (1)
Studies
Open first, then newest update. How each study uses sugemalimab is read from its arms, and is right about nine times in ten.
Testing it · 16
- Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell LymphomaNot yet recruitingPhase 3CStone PharmaceuticalsNCT05700448Written as Sugemalimab
- Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLCRecruitingPhase 1/2Sichuan UniversityNCT06217757Written as Sugemalimab
- Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLCRecruitingNot applicablePeking Union Medical CollegeNCT07247227Written as Sugemalimab and Chemotherapy
- Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRTRecruitingPhase 2/3Sun Yat-sen UniversityNCT05623267Written as Sugemalimab
- A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLCRecruitingPhase 2Hunan Cancer HospitalNCT05940532Written as Sugemalimab and Chemotherapy
- A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung CancerCompletedPhase 3CStone PharmaceuticalsNCT03789604Written as CS1001 monoclonal antibody
- A Study of CS1001 in Subjects with Advanced Solid TumorsCompletedPhase 1CStone PharmaceuticalsNCT03744403Written as CS1001
- A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)CompletedPhase 2CStone PharmaceuticalsNCT03595657Written as CS1001
- Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC PatientsCompletedPhase 1CStone PharmaceuticalsNCT04421352Written as CS1001
- A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction AdenocarcinomaCompletedPhase 3CStone PharmaceuticalsNCT03802591Written as CS1001 monoclonal antibody
- A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedPhase 3CStone PharmaceuticalsNCT04187352Written as CS1001+ Fluorouracil+Cisplatin
- A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung CancerCompletedPhase 3CStone PharmaceuticalsNCT03728556Written as CS1001 monoclonal antibody
- A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid TumorsStatus unknownPhase 1Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT04472858Written as CS1001
- A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin LymphomaCompletedPhase 2CStone PharmaceuticalsNCT03505996Written as CS1001
- A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid TumorsCompletedPhase 1CStone PharmaceuticalsNCT03312842Written as CS1001
- A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid TumorsCompletedPhase 1/2CStone PharmaceuticalsNCT04200404Written as CS1001
Given in every arm · 1 — sugemalimab is usual care beside what is tested
As the comparator · 1 — what is tested is compared with sugemalimab
Codes
What other systems call sugemalimab · ClinicalTrials.gg INT001923
- MeSH (NLM) C000723018sugemalimabOne source ClinicalTrials.gov
- UNII (FDA) 90IQR2I6TRSUGEMALIMABOne source FDA
- NCI Thesaurus C154550SugemalimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000723018 | sugemalimab | One source ClinicalTrials.gov |
| UNII (FDA) | 90IQR2I6TR | SUGEMALIMAB | One source FDA |
| NCI Thesaurus | C154550 | Sugemalimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.